A detailed history of Jane Street Group, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 85,667 shares of RLMD stock, worth $338,384. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,667
Previous 114,354 25.09%
Holding current value
$338,384
Previous $68,000 152.94%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

SELL
$0.56 - $2.01 $16,064 - $57,660
-28,687 Reduced 25.09%
85,667 $172,000
Q2 2025

Aug 14, 2025

BUY
$0.25 - $0.83 $28,588 - $94,913
114,354 New
114,354 $68,000
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $403,616 - $680,499
-137,753 Reduced 78.61%
37,476 $112,000
Q1 2024

May 15, 2024

BUY
$3.1 - $6.8 $505,591 - $1.11 Million
163,094 Added 1344.0%
175,229 $814,000
Q4 2023

Feb 14, 2024

BUY
$2.45 - $4.22 $29,730 - $51,209
12,135 New
12,135 $50,000
Q2 2023

Aug 14, 2023

BUY
$2.22 - $3.54 $26,901 - $42,897
12,118 New
12,118 $29,000
Q4 2022

Feb 14, 2023

BUY
$2.17 - $35.84 $257,325 - $4.25 Million
118,583 New
118,583 $413,000
Q2 2022

Aug 16, 2022

SELL
$16.5 - $30.34 $716,017 - $1.32 Million
-43,395 Reduced 77.85%
12,348 $234,000
Q1 2022

May 17, 2022

BUY
$16.72 - $26.99 $932,022 - $1.5 Million
55,743 New
55,743 $1.51 Million
Q3 2021

Nov 16, 2021

SELL
$21.86 - $34.77 $413,569 - $657,813
-18,919 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$29.55 - $39.15 $559,056 - $740,678
18,919 New
18,919 $606,000
Q3 2020

Nov 17, 2020

SELL
$34.42 - $43.78 $643,585 - $818,598
-18,698 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$31.59 - $49.98 $339,971 - $537,884
10,762 Added 135.61%
18,698 $836,000
Q1 2020

May 15, 2020

BUY
$23.78 - $50.12 $188,718 - $397,752
7,936 New
7,936 $271,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $113M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.